Navigation Links
Prototype test for predicting clinical outcome for melanoma patients
Date:8/14/2008

enefit by comparing patients who receive the new therapy with those who do not. Although patients might all have the same type of cancers, there can be big differences in their survival simply because their cancers behave differently - and this may have nothing to do with the treatment. If we are able to identify the good players and the bad players up-front, it becomes a whole lot easier figuring out whether good results are due to the new treatment or not. Most importantly far fewer patients would be needed for the clinical trials. It's partly because we can't clinically identify subtypes of patients that we have to do very large and very expensive trials. And, of course, this increases the time it takes to test the clinical benefit of potential new therapies."

The joint Australian/New Zealand team used microarrays to measure the expression of more than 30,000 genes in lymph node sections taken from 29 patients with Stage III melanoma. There were 2,140 genes differentially expressed in the sections from people who had already had a "poor" outcome (average TTP of just four months) and patients that had had a "good" outcome (average TTP of 40+ months). Using statistical analyses, the team identified 21 genes that could be used to differentiate between the two subtypes of patients in the retrospective analysis. This gene signature was then used to prospectively analyze another 10 patients, with the clinical outcome for nine of the 10 (90%) patients proving to be predicted accurately. The one patient who was incorrectly predicted to have a "good" prognosis did have a rapid TTP to Stage IV. However, this patient went on to have a prolonged survival of six years. The team also applied the test to published data sets and showed they could get a prediction accuracy of 85%, event though data was not available for all 21 genes in the published literature.

This study was conducted under the auspices of the Hilton Ludwig Cancer Metastasis Initiative. It was
'/>"/>

Contact: Sarah L. White
swhite@licr.org
917-379-0398
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Intervention for Adults with Autism Spectrum Disorder Prototype Completed by SIMmersion LLC
2. STMicroelectronics and Debiotech Announce First Prototypes of Disposable Insulin Nanopump
3. Shopko Announces New Prototype Store in Council Bluffs
4. Research highlights problems of predicting birthweights in obese mothers
5. Predicting post-traumatic stress disorders in deployed veterans
6. Predicting the future in ovarian cancer
7. Predicting survival after liver transplantation
8. Blood test takes step toward predicting Alzheimers risk, Stanford researchers find
9. Use of certain lipid measures not more effective in predicting coronary heart disease
10. Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads
11. Clinical Research Management gets contract for trials of therapeutics against infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... The establishment and creation of ... one of the main strategies of the Church ... impact around the world. , Architecturally stellar buildings ... executives and trainers deliver L. Ron Hubbard's spiritual ... statistics demonstrate that significant reduction in crime, major ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, ... Disease, Dementia, and Memory Loss . , Country singer Glen ... with the Alzheimer’s, inspired Seniors Guide writers to review the ... movie, out on October 14, 2014, shows a glimpse of ... disease – which inspires a final tour from the musician ...
(Date:8/30/2014)... By Randy Dotinga ... -- About one in five patients operated on for broken ... after surgery, a new study finds. Less-educated patients ... times more likely to be "doctor shoppers," said study lead ... Lexington, Ky. Overall, he said, the study suggests that doctors ...
(Date:8/30/2014)... commonly used to treat gout, before and after ... complications from this type of surgery, but it ... according to a study published by JAMA ... to coincide with its presentation at the European ... cardiac surgery include postpericardiotomy syndrome (the occurrence of ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's #1 ... Day discount on all SEO services. While working with ... related to internet marketing. Their dedicated team of professionals ... have a deep understanding for their specialization. This further ... since the inception, they have worked with over 5000 ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... ARLINGTON, Va., Nov. 16 Acknowledging that their results ... in the International Journal of Andrology nevertheless attempt to link ... to maternal exposure to phthalates. The researchers, led by ... previous, and much publicized, study of phthalate exposure to evaluate ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... Company will hold a teleconference and webcast at 8:00 a.m. Eastern ... Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of ... Conference Call and Webcast Information , To participate ...
... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
... ... its intention to begin the drug registration process in Brazil and Colombia for its ... United States for the treatment of moderate to severe (Stage 2) chronic pain. ... Plantation, FL (Vocus) ...
... , ... from the RecordAF,registry (REgistry on Cardiac rhythm disORDers assessing ... Sessions of the,American Heart Association, show that in recently ... rhythm-control strategy,provides better short term control of the arrhythmia ...
... when new lead is needed in heart devices, ... -- Replacing or adding wiring increases the risk ... replace a pacemaker or other heart rhythm-stabilizing device, ... complication rates among patients enrolled in the REPLACE ...
Cached Medicine News:Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 2Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 3Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 5
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... September 15 NicOx S.A. (Euronext,Paris: COX) today ... study for naproxcinod in 1020 patients with osteoarthritis ... naproxcinod (750 mg and 375 mg bid) met,the ... study,also comfortably met the main secondary endpoint, demonstrating ...
... ... Osteoarthritis, WALTHAM, ... announced today that Kenneth Kornman, Ph.D.,the company,s Chief Scientific Officer, ... (OA) at the 2008 World Congress,on Osteoarthritis, sponsored by the ...
Cached Medicine Technology:NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 2NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 3NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 4NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 5Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 2Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 3Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 4
... to having been designed exclusively for vascular treatments, ... the Smartepil range which ensures fast amortisation of ... systems, it can be fitted with a polarised ... the target to be treated as well as ...
... SmartLite Derm is a KTP laser, ... of 532 nm (frequency doubled Nd:YAG) for ... by the comfortable color LCD Touch-screen. ... available are 0.3, 0.5, 0.7 and 1.0 ...
... a new and powerful instrument for ... system (MEL @308 nm - UVB) ... vitiligo. Designed to treat recalcitrant plaques, ... exposure of extensive lesions without irradiating ...
... a CO2 laser system with CW intensities ... dealing with all therapeutic application in modern ... medium-to-high intensities in super-pulsed mode, designed for ... It is also capable of supplying soft ...
Medicine Products: